|Mr. Richard Marsden||Chief Exec. Officer, MD & Exec. Director||N/A||N/A||50|
|Mr. John Ward||Fin. Director, Company Sec. & Exec. Director||156k||220.5k||56|
|Dr. Phillip David Monk||Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director||143k||293.15k||49|
|Prof. Donna Davies||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Prof. Ratko Djukanovic||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-??), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-?? that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in preclinical development for the treatment of idiopathic pulmonary fibrosis (IPF). Synairgen plc has research collaboration with Pharmaxis Ltd. to develop a LOXL2 inhibitor to the lysyl oxidase type 2 enzyme to treat IPF, a lung disease. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.